AHK-Cu is a synthetic analog of GHK-Cu with an acetylated N-terminus that increases tissue retention and extends half-life from approximately 90 minutes (GHK-Cu) to an estimated 68 hours (AHK-Cu)
In rat studies, the peptide produced a 64.5% reduction in wound size over 13 days, compared to 45.6% for vehicle-treated and 28.2% for untreated controls
Doses and half-lives are conventions, not pharmacology
Regulation of gene expression by zinc-related enzymes Zinc-related enzymes can influence gene expression, thereby regulating various cell physiological processes
N -hexanoic-Tyr-Ile-(6)-aminohexanoic amide, CAS 1401708-83-5) is a small, metabolically stabilized angiotensin IV (AngIV) analog engineered to survive the gut and cross the blood-brain barrier after oral dosing [1]
Novo Nordisk knows this the higher-dose 2.4/7.2 mg trial planned for H2 2026 is designed to close that gap